Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability to combat the rare genetic…
News
Nonalcoholic steatohepatitis, or NASH, might be prevented by treatments able to target certain immune cells, according to a recent study in mice which demonstrated that the condition has…
FATTY LIVER DISEASE
NewsAlbireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis…
FATTY LIVER DISEASE
NewsMonkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in…
Researchers presented more than 50 studies highlighting the benefits of Accuray’s CyberKnife System at the 36th Annual European Society for Radiotherapy and Oncology (ESTRO)…
FATTY LIVER DISEASE
NewsEarly Study to Test Bioelectronic Treatment for NASH Inflammation
A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced.
Durect has signed an agreement with Sandoz to develop and market Posimir (Saber-bupivacaine), an investigational localized pain reliever, in the United States. Durect…
CHOLANGITIS
NewsGenkyotex’s GKT831 Drug Moves to Phase 2 Trial After Winning FDA Investigational New Drug Status
The U.S. Food and Drug Administration (FDA) has granted investigational new drug (IND) status to GKT831, allowing French pharmaceutical company Genkyotex to advance its drug to a Phase…
Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed…
GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary…
Recent Posts
- Breastmilk helps babies recover after Kasai surgery, study shows
- Bepirovirsen under review in Europe as a treatment for chronic hepatitis B
- ALF marks Donate Life Month in April with focus on living liver donors
- Why we might cancel a doctor’s appointment (and why we shouldn’t)
- Inflammation markers may predict fetal risk in ICP: Study